Document 0851
 DOCN  M9440851
 TI    [Pneumocystis carinii pneumonia during therapy with
       2-chlorodeoxyadenosine (2-CDA)]
 DT    9404
 AU    Haberthur C; Pless M; Tichelli A; Gratwohl A; Speck B; Betticher DC;
       Departement Innere Medizin, Kantonsspital Basel.
 SO    Schweiz Med Wochenschr. 1994 Jan 11;124(1-2):73-8. Unique Identifier :
       AIDSLINE MED/94126703
 AB    We report the case of a 70-year-old patient with B-cell chronic
       lymphocytic leukemia. During therapy with the new purine analog
       2-chloro-deoxyadenosine (2-CDA) the patient developed Pneumocystis
       carinii pneumonia (PCP). Although the mechanism of action of 2-CDA
       suggests the incidence of opportunistic infections and therefore
       pneumocystis pneumonia, this is the first case of PCP among 140 patients
       of the Swiss study of 2-CDA. The mechanism of action of 2-CDA is
       described and the occurrence of PCP among patients without acquired
       immunodeficiency syndrome is discussed.
 DE    Aged  Case Report  English Abstract  Female  Human  Leukemia,
       Lymphocytic, Chronic/*DRUG THERAPY  Pneumonia, Pneumocystis
       carinii/*COMPLICATIONS  2-Chlorodeoxyadenosine/ADVERSE
       EFFECTS/*THERAPEUTIC USE  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).